Eligibility for Cardiovascular Risk Reduction Therapy in the United States Based on SELECT Trial Criteria: Insights From the National Health and Nutrition Examination Survey
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 17 (1) , e010640
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine, 2023
- Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristicsObesity, 2022
- Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and designAmerican Heart Journal, 2020